| 000 | 01621 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517150347.0 | ||
| 264 | 0 | _c20180130 | |
| 008 | 201801s 0 0 eng d | ||
| 022 | _a1742-7843 | ||
| 024 | 7 |
_a10.1111/bcpt.12796 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHansen, Morten Rix | |
| 245 | 0 | 0 |
_aTherapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration Relationships. _h[electronic resource] |
| 260 |
_bBasic & clinical pharmacology & toxicology _cOct 2017 |
||
| 300 |
_a298-302 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntidepressive Agents, Second-Generation _xadministration & dosage |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 | _aDenmark |
| 650 | 0 | 4 |
_aDesvenlafaxine Succinate _xblood |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDrug Monitoring _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMethylation |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSex Factors |
| 650 | 0 | 4 |
_aVenlafaxine Hydrochloride _xadministration & dosage |
| 700 | 1 | _aKuhlmann, Ida Berglund | |
| 700 | 1 | _aPottegård, Anton | |
| 700 | 1 | _aDamkier, Per | |
| 773 | 0 |
_tBasic & clinical pharmacology & toxicology _gvol. 121 _gno. 4 _gp. 298-302 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bcpt.12796 _zAvailable from publisher's website |
| 999 |
_c27069196 _d27069196 |
||